Usefulness of intravenous abatacept at an increased dose in rheumatoid arthritis patients with a poor prognosis

Usefulness of intravenous abatacept at an increased dose in rheumatoid arthritis patients with a poor prognosis - Intravenous abatacept at an increased dose in RA patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011789

Enrollment

Registered

2013-09-20

Start date

2010-09-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Administration of increased dose of abatacept to patients with rheumatoid arthritis previously treated with abatacept.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with rheumatoid arthritis (meeting the ACR criteria in 2010) 2. Patients who had a response to intravenous treatment with ABT at a dose of 2 vials within 3 months before dose increase and had less than 4% decrease in DAS28-ESR over 4 weeks before dose increase 3. Patients who gave oral presentation of informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The effect of dose increase of abatacept: 1. Number of painful joints 2. Number of swollen joints 3. VAS (patient's global assessment) 4. VAS (physician's global assessment) 5. Erythrocyte sedimentation rate 6. CRP 7. DAS28-ESR 8. DAS28-CRP 9. mHAQ 10. MMP-3	—

Secondary

Measure	Time frame
1. DAS28-ESR and DAS28-CRP according to the dose per kg body weight 2. EULAR Response 3. ACR20 4. Adverse events	—

Countries

Japan

Contacts

Public ContactDaihei Kida

National Health Organization Nagoya Medical Center Orthopedic Surgery and Rheumatology

kidad@nnh.hosp.go.jp052-951-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026